Breast cancer remains a significant health challenge worldwide, characterized by its diverse subtypes and varying prognoses. Among these, triple-negative breast cancer (TNBC) is particularly aggressive and lacks targeted therapies due to the absence of estrogen receptors, progesterone receptors, and HER2 expression. The heterogeneity of tumors in the TNBC subtype complicates treatment strategies, as diverse cellular subpopulations exhibit different molecular characteristics and responses to therapy. Key signaling pathways, such as the AKT pathway, play critical roles in the progression and survival of TNBC cells. Similarly, the RUNX family of transcription factors has emerged as an influential player in TNBC, regulating genes involved in cell proliferation, differentiation, and apoptosis. Recent studies highlight the intricate cross-talk between the AKT pathway and the transcriptional activity of different isoforms of RUNX, which may contribute to the aggressive nature of TNBC. Understanding this interaction provides new insights into potential therapeutic targets, offering hope for more effective treatments for patients with this challenging breast cancer subtype. This review explores the complex tumor heterogeneity in TNBC, the fundamental roles of AKT and RUNX, and their interaction, with the aim of illuminating new avenues for interdisciplinary intervention and improving clinical outcomes in breast cancer in general and TNBC in particular.